Document Type

Article

Abstract

Introduction

This systematic review evaluates the extent to which the effect of anticoagulants may be altered in the presence of cannabinoids.

Methods

The following databases were searched: EMBASE, PubMed, Web of Science, Scopus, PscycINFO, and CINAHL from database inception through May 2023. Search terms included cannabis AND anticoagulant AND drug interactions, and related key words. The major outcome was hemorrhage or thrombosis and if available, the relative change in quantitative intensity of anticoagulation after cannabinoid exposure.

Results

The search generated 959 citations. After removal of 440 duplicates, 519 citations were screened. Overall, with the exception of warfarin, evidence supporting an interaction between cannabinoids and anticoagulants is non-existent. Seven case reports evaluating an interaction with warfarin were reported. Cannabis doses involved were either extremely high (e.g., >260 mg/day of delta-9-tetrahydrocannabidiol [THC] or >600 mg/day of cannabidiol [CBD]) or were not known. Hemorrhage was identified in 14.2% (1/7) of reports and thrombosis in 0%. Quantitative anticoagulation levels were increased in patients on warfarin (elevated International Normalized Ratio [INR]) in 6 of 7 cases. A maximum INR change was available in 5 of 7 reports, ranging from +0.4 to +9.61. One report found no change in INR after 4 days of medical cannabis exposure. Another report outlined two separate episodes of INR elevation associated with bleeding requiring hospitalization and reversal after marijuana smoking. Four cases involved reduction in weekly warfarin dose ranging from 22% to 31%. The Drug Information Probability Score was calculated in 6 cases, with a score of probable for 5 cases and possible for one.

Conclusions

Very low-quality data support a potential drug-drug interaction with warfarin and both THC and CBD. Clinician recognition of this potential interaction is important. Available evidence supports the need to conduct a drug interaction study between cannabinoids and warfarin to clarify the existence of an interaction.

Disciplines

Pharmacy and Pharmaceutical Sciences

Comments

This is the peer-reviewed version of the following article in press:

Smythe MA, Wu W, Garwood CL. Anticoagulant Drug-Drug Interactions with Cannabinoids: A Systematic Review. Pharmacotherapy. 2023. https://doi.org/10.1002/phar.2881

The following language is required by Wiley:

This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.

Available for download on Sunday, September 01, 2024

Share

COinS